Currently out of the existing stock ratings of Jim Molloy, 46 are a BUY (93.88%), 2 are a SELL (4.08%), 1 are a HOLD (2.04%).

Jim Molloy

Work Performance Price Targets & Ratings Chart

Analyst Jim Molloy, currently employed at ALLIANCE GLOBAL PARTNERS, carries an average stock price target met ratio of 46.15% that have a potential upside of 22.8% achieved within 181 days.

Jim Molloy’s has documented 93 price targets and ratings displayed on 18 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on TNXP, Tonix Pharmaceuticals Holding Corp at 01-Aug-2023.

Wall Street Analyst Jim Molloy

Analyst best performing recommendations are on TNXP (TONIX PHARMACEUTICALS HOLDING CORP).
The best stock recommendation documented was for TNXP (TONIX PHARMACEUTICALS HOLDING CORP) at 1/12/2023. The price target of $6.5 was fulfilled within 6 days with a profit of $1 (13.33%) receiving and performance score of 22.22.

Average potential price target upside

of $87.31 (77.49%) on RMTI (ROCKWELL MEDICAL).
of $55.56 (32.92%) on TNXP (TONIX PHARMACEUTICALS HOLDING CORP).
of $7.59 (72.85%) on AVDL (AVADEL PHARMACEUTICALS PLC).

ICPT Intercept Pharmaceuticals HTBX Heat Biologics TNXP Tonix Pharmaceuticals Holding Corp ALIM Alimera Sciences AQST Aquestive Therapeutics BCDA Biocardia CANF Can Fite Biopharma Ltd ADR ENVB Enveric Biosciences ETTX Entasis Therapeutics Holdings NHWK Nighthawk Biosciences OCUP Ocuphire Pharma ORMP Oramed Pharmaceuticals PSTI Pluristem SLS Sellas Life Sciences Group SNGX Soligenix AVDL Avadel Pharmaceuticals PLC CARA Cara Therapeutic RMTI Rockwell Medical

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Ed Arce (HC WAINWRIGHT)